Literature DB >> 9809193

Cortisol and hypertension.

J J Kelly1, G Mangos, P M Williamson, J A Whitworth.   

Abstract

1. In humans, the hypertensive effects of adrenocorticotropic hormone (ACTH) infusion are reproduced by intravenous or oral cortisol. Oral cortisol increases blood pressure in a dose-dependent fashion. At a dose of 80-200 mg/day, the peak increases in systolic pressure are of the order of 15 mmHg. Increases in blood pressure are apparent within 24 h. 2. Cortisol-induced hypertension is accompanied by a significant sodium retention and volume expansion. Co-administration of the type I (mineralocorticoid) receptor antagonist spironolactone does not prevent the onset of cortisol-induced hypertension. Thus, sodium retention is not the primary mechanism of cortisol-induced hypertension. 3. Direct and indirect measures of sympathetic activity are unchanged or suppressed during cortisol administration, suggesting that cortisol-induced hypertension is not mediated by increased sympathetic tone. 4. Preliminary evidence in humans suggests that suppression of the nitric oxide system may play a role in cortisol-induced hypertension. 5. These potential mechanisms of cortisol action may be relevant in a number of clinical contexts, including Cushing's syndrome, apparent mineralocorticoid excess, the hypertension of liquorice abuse and chronic renal failure. There is also preliminary evidence suggesting a role for cortisol in essential hypertension.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9809193     DOI: 10.1111/j.1440-1681.1998.tb02301.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol Suppl        ISSN: 0143-9294


  37 in total

1.  Glucocorticoid treatment and cardiovascular disease.

Authors:  M K C Ng; D S Celermajer
Journal:  Heart       Date:  2004-08       Impact factor: 5.994

2.  New-onset acute heart failure after intravenous glucocorticoid pulse therapy in a patient with Graves' ophthalmopathy.

Authors:  Alptekin Gursoy; Mustafa Cesur; Murat Faik Erdogan; Demet Corapcioglu; Nuri Kamel
Journal:  Endocrine       Date:  2006-06       Impact factor: 3.633

Review 3.  Tissue-specific dysregulation of 11beta-hydroxysteroid dehydrogenase type 1 and pathogenesis of the metabolic syndrome.

Authors:  P Putignano; F Pecori Giraldi; F Cavagnini
Journal:  J Endocrinol Invest       Date:  2004-11       Impact factor: 4.256

4.  Circadian blood pressure profile in patients with Cushing's syndrome before and after treatment.

Authors:  S Zacharieva; M Orbetzova; A Stoynev; R Shigarminova; M Yaneva; K Kalinov; E Nachev; A Elenkova
Journal:  J Endocrinol Invest       Date:  2004-11       Impact factor: 4.256

Review 5.  Corticosteroid-induced adverse events in adults: frequency, screening and prevention.

Authors:  Laurence Fardet; Abdulrhaman Kassar; Jean Cabane; Antoine Flahault
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

6.  Adverse Childhood Experiences (ACEs) Predict Increased Arterial Stiffness from Childhood to Early Adulthood: Pilot Analysis of the Niagara Longitudinal Heart Study.

Authors:  Talha Rafiq; Deborah D O'Leary; Kylie S Dempster; John Cairney; Terrance J Wade
Journal:  J Child Adolesc Trauma       Date:  2020-05-30

7.  The role of sustained release isosorbide mononitrate on corticosteroid-induced hypertension in healthy human subjects.

Authors:  P M Williamson; S L H Ong; J A Whitworth; J J Kelly
Journal:  J Hum Hypertens       Date:  2015-03-26       Impact factor: 3.012

Review 8.  Vascular effects of maternal alcohol consumption.

Authors:  Jayanth Ramadoss; Ronald R Magness
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-06-22       Impact factor: 4.733

9.  Insomnia and its association with hypertension in a community-based population in China: a cross-sectional study.

Authors:  Yiqiang Zhan; Ruoqing Chen; Fen Zhang; Jinsong Wang; Yihong Sun; Rongjing Ding; Dayi Hu; Jinming Yu
Journal:  Heart Asia       Date:  2014-06-21

Review 10.  Neuroendocrine drivers of risk and resilience: The influence of metabolism & mitochondria.

Authors:  Susie Turkson; Alix Kloster; Peter J Hamilton; Gretchen N Neigh
Journal:  Front Neuroendocrinol       Date:  2019-07-06       Impact factor: 8.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.